深 沪
undefined undefined
--
NaN.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 --
- 52周最高 --
- 市盈率 静 NaN.00
- 换手率 NaN.00%
- 52周最低 --
- 委 比 --
- 总股本 --
- 历史最高 --
- 量 比 --
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 --
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’
AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settle at $5.32 during the session.
07-24 19:53
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.
07-20 22:45
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.
07-01 00:31
Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report
US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials conducted in China.
06-30 21:13
AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins
FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest updates.
06-30 01:04
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.
06-24 01:11
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 points on Monday. The Dow traded up 0.28% to 51,709.06 while the NASDAQ fell 1.31% to 26,170.77. The S&P 500 also
06-23 00:05
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
Reported Friday, 'AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics' - FT
https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1
06-22 16:24
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
AbbVie says nine-year CLL14 data showed longer progression-free survival with venetoclax plus obinutuzumab in chronic lymphocytic leukemia.
06-12 22:30
